Directors Gaby L. Longsworth, Ph.D., Marsha R. Gillentine, Ph.D., and Eric K. Steffe, outline the consequences of the recent Federal Circuit ruling in Gilead Sciences v. Natco Pharma Ltd. Published in The Patent Lawyer, this report details the scope of obviousness-type double patenting (ODP). The authors note that “The ruling in Gilead could have major ramifications for the term of a significant number of existing patents. This is particularly true in the biotech and pharma industries where prosecution of multiple applications in the same family and related families is common.”

To read the full article, please download the attached PDF.

Related Industries

Related Services